Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development
Daiichi Sankyo is saying goodbye to one of its longtime subsidiaries.
The multinational pharma company announced Wednesday it will shut down all operations of Plexxikon, which it acquired in a $935 million buyout back in 2011. In a release, Daiichi said it’s closing Plexxikon’s offices to “maximize its R&D investment” in its major cancer drug Enhertu as well as two other ADC programs, Dato-DXd and HER3-DXd.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.